Lilly's oral obesity pill debuts
- The FDA approved Eli Lilly's oral obesity pill Foundayo, which began prescriptions immediately in the U.S. - PharmExec reported the pill was prescribed over 1,000 times in its first days, and Lilly said Foundayo met primary heart-safety goals in a diabetes trial. - Strong early demand faces friction from insurers and PBMs dropping coverage, meaning patient uptake may not directly translate into sustained revenue without reimbursement fixes. (bonnercountydailybee.com; pharmexec.com; npr.org)
Eli Lilly’s new obesity pill, Foundayo, is already moving into U.S. pharmacies after the Food and Drug Administration cleared it on April 1. (fda.gov; investor.lilly.com) Foundayo is Lilly’s brand name for orforglipron, a once-daily GLP-1 pill for adults with obesity, or overweight with weight-related medical problems. Lilly said prescriptions were accepted immediately through LillyDirect and shipping began April 6 before broader U.S. retail rollout. (investor.lilly.com) GLP-1 drugs copy a gut hormone that helps people feel fuller and eat less, but this market has been dominated by weekly injections such as Wegovy and Zepbound. Foundayo gives Lilly an oral option in the same race, with Novo Nordisk already selling an oral Wegovy tablet in the U.S. (verywellhealth.com; pharmexec.com) Early demand was measurable within days. PharmExec, citing IQVIA data discussed by RBC Capital Markets, reported 1,390 U.S. prescriptions in Foundayo’s first days on the market, while USA Today reported Lilly began taking prescriptions on April 1 and started shipping on April 6. (pharmexec.com; usatoday.com) Lilly also used launch week to release new safety data from ACHIEVE-4, a late-stage diabetes trial. The company said Foundayo met the study’s primary cardiovascular endpoint by showing heart-safety non-inferiority against insulin glargine in adults with type 2 diabetes who also had obesity or were overweight and at higher cardiovascular risk. (investor.lilly.com; fiercepharma.com) The Food and Drug Administration’s approval did not end the reimbursement fight. NPR reported this week that coverage for obesity drugs has tightened, with plans and pharmacy benefit managers dropping or restricting coverage for products including Lilly’s Zepbound and Novo Nordisk’s Wegovy. (houstonpublicmedia.org; wwno.org) NPR cited a GoodRx analysis showing 12 million people lost coverage for Zepbound over the last year, and 12 million also lost coverage for Wegovy. Pharmaphorum reported that CVS Health kept Wegovy on a major formulary while dropping Zepbound after negotiating with Novo Nordisk. (houstonpublicmedia.org; pharmaphorum.com) That leaves Lilly with two tracks at once: strong consumer interest in a pill and uneven payment support from insurers. If Foundayo keeps drawing prescriptions but coverage stays narrow, Lilly may have to lean harder on cash-pay channels such as LillyDirect while it pushes for broader formulary access. (investor.lilly.com; pharmexec.com; houstonpublicmedia.org)
